UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. 2173 Salk Avenue, Suite 200 Carlsbad, California 92008 (Address of principal e ...

The future of cell therapy. Corporate Overview Brian M. Culley, Chief Executive Officer September 14, 2020 Forward-Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Lineage Cell Therapeutics, Inc. ("Lineage"). This presentation includes certain information obtained from trade and statistical services, third-party publications, and other sources. Lineage has not independently verified such information and ...

The future of cell therapy. LD Micro 500 Virtual Investor Conference Brian M. Culley, Chief Executive Officer September 1, 2020 Forward-Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Lineage Cell Therapeutics, Inc. ("Lineage"). This presentation includes certain information obtained from trade and statistical services, third-party publications, and other sources. Lineage has not independently verified ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q2 2020 Earnings Conference Call August 6, 2020 5:30 PM ET Corporate Participants Ioana Hone - Director, Investor Relations Brian Culley - Chief Executive Officer Brandi Roberts - Chief Financial Officer Gary Hogge - Senior Vice President, Clinical and Medical Affairs Conference Call participants Joe Pantginis - H.C. Wainwright Dane Leone - Raymond James Operator Welcome to the Lineage Cell Therapeutics Second Quarter 2020 Conference Call. At this time, all partic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _______ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. California 94-3127919 (State or other jurisdiction of incorporation or organization) ...

The future of cell therapy. 2020 Solebury Trout Virtual Investor Conference Brian M. Culley, Chief Executive Officer May 26, 2020 Forward-Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Lineage Cell Therapeutics, Inc. ("Lineage"). This presentation includes certain information obtained from trade and statistical services, third-party publications, and other sources. Lineage has not independently verifi ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q1 2020 Earnings Conference Call May 7, 2020 4:30 PM ET Company Participants Ioana Hone - Director, IR Brian Culley - CEO Brandi Roberts - CFO Conference Call Participants Jason McCarthy - Maxim Group Joe Pantginis - H.C. Wainwright Operator Welcome to the Lineage Cell Therapeutics First Quarter 2020 Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available on the Investors section of Lineage website at w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 (Stat ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q4 2019 Earnings Conference Call March 12, 2020 4:30 PM ET Company Participants Ioana Hone - Director of Investor Relations Brian Culley - Chief Executive Officer Brandi Roberts - Chief Financial Officer Gary Hogge - Senior Vice President, Clinical and Medical Affairs Conference Call Participants Joe Pantginis - H.C. Wainwright Keay Nakae - Chardan Capital Operator Ladies and gentlemen, welcome to the Lineage Cell Therapeutics Fourth Quarter and Full Year 2019 Fi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________ to __________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...